Bio-Techne (TECH) Restructuring Costs (2013 - 2014)
Bio-Techne (TECH) posted quarterly Restructuring Costs of $2.4 million for Q3 2014, up 345.49% year-over-year from $532000.0 in Q3 2013, and up 345.49% quarter-over-quarter from $532000.0 in Q3 2013.
Powered by 
Analysis
Bio-Techne (TECH) Restructuring Costs (2013 - 2014) Analysis & Trends
Bio-Techne's Restructuring Costs history runs 2 years deep, the most recent figure standing at $2.4 million for Q3 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Bio-Techne | 11.30 Bn | 11.03 Bn | 211.39 Mn |